Galapagos raises EUR54 million MECHELEN,

New Post Public Reply Private Reply Replies (0) Message Board
testuser
Galapagos raises EUR54 million

MECHELEN, BELGIUM--(Marketwired - Apr 24, 2013) - Galapagos NV ( EURONEXT BRUSSELS : GLPG ) announced today that it has raised EUR53.9 million through a private placement of new shares via an accelerated bookbuilding procedure announced on 24 April 2013.

Galapagos has placed 2,696,831 new shares to qualified institutional investors in the United States and Europe at a price of EUR20.00 per share, a 1.7% discount to the previous day's closing price. The placed shares comprise just below 10% of the current number of outstanding shares, bringing the total number of shares after the issue to 29,665,159. The new shares will be admitted to trading on NYSE Euronext Brussels and NYSE Euronext Amsterdam following their issuance, which is expected to take place on 30 April 2013.

The net proceeds from the transaction will be used primarily for general corporate purposes and will also give Galapagos additional balance sheet flexibility to enable the Company to further fund attractive internal pipeline opportunities before considering a partnership, and also to undertake attractive inlicensing or acquisition opportunities should they fit with Company strategy.

Jefferies International Limited and Kempen & Co. acted as Joint Global Coordinators and Joint Bookrunners for the offering.

About Galapagos

Galapagos ( EURONEXT BRUSSELS : GLPG ) ( PINKSHEETS : GLPYY ) is specialized in novel modes-of-action, with a large pipeline of four clinical, seven pre-clinical, and 30 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, about to enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization after Phase 2b. Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptor antagonist currently in a Phase 1b patient study in metastasis. GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically for the treatment of IBD; this program is currently in a Proof of Concept Phase 2 study, with results expected early 2014. The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has around 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. Further information at: www.glpg.com

IMPORTANT INFORMATION

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

The distribution of this press release in certain jurisdictions may be restricted by law. No action has been taken by Galapagos, Jefferies International Limited, Kempen & Co N.V. or any of their respective affiliates that would permit a public offer of the new shares in any jurisdiction where action for that purpose is required. This press release is for information purposes only and does not constitute an offer to purchase or the solicitation of an offer to buy any new shares in any jurisdiction in which such an offer or solicitation is unlawful. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.

This press release is not for publication or distribution, directly or indirectly, in the United States (including its territories and possessions, any state of the United States and the District of Columbia), Canada, Australia and Japan. This press release does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States, nor does it constitute an offer to sell, or the solicitation of an offer to buy, and there shall not be any sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to its registration or qualification under the laws of such jurisdiction. The new shares mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "Securities Act"). The new shares may not be offered or sold in the United States except pursuant to an effective registration statement under, or an exemption from the registration requirements of, the Securities Act. There will be no public offer of securities in the United States.

This press release is not an offer to sell nor a solicitation to buy the new shares nor a prospectus for the purposes of Directive 2003/71/EC (such Directive, together with any applicable implementing measures in the relevant member state of the European Economic Area and as amended, including by Directive 2010/73/EU, to the extent implemented in the relevant member state, the "Prospectus Directive"). There will be no offer to the public of the new shares in any member state of the European Economic Area and no prospectus or other offering document has been or will be prepared in connection with the sale of the new shares by the Company. In the European Economic Area the new shares will only be offered and sold to "qualified investors" as defined in the Prospectus Directive or in other circumstances falling within Article 3(2) of the Prospectus Directive.

This press release does not constitute an offer of the new shares to the public in the United Kingdom, nor is it intended to be an inducement to engage in investment activity for the purpose of section 21 of the Financial Services and Markets Act 2000 (as amended) of the United Kingdom. Consequently, this press release is only directed at (i) persons who are outside the United Kingdom; (ii) investment professionals within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 as amended (the "Order"); (iii) persons falling within Article 49(2)(a)-(d) of the Order; or (iv) other persons to whom it may be lawfully be communicated, together being referred to as "relevant persons". The new shares are only available to, and any invitation, offer or agreement to purchase or otherwise acquire the new shares will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

This press release does not constitute or form part of, and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase the new shares, and nothing contained therein shall form the basis of or be relied on in connection with any contract or commitment whatsoever, nor does it constitute a recommendation regarding the new shares. An investment decision to buy any of the new shares in the private placement must be made solely on the basis of publicly available information. Such information is not the responsibility of, and has not been independently verified by any of, Jefferies International Limited, Kempen & Co N.V., or their respective affiliates.

Jefferies International Limited, Kempen & Co N.V. are acting only for the Company in connection with the private placement and no one else, and will not be responsible to anyone other than the Company for providing the protections offered to clients of Jefferies International Limited, Kempen & Co N.V. nor for providing advice in relation to the private placement.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE

[HUG#1696104]

CONTACT Galapagos NV Elizabeth Goodwin Director Investor Relations Tel: +31 6 2291 6240 Email Contact

Investors-Hangout-Stock-Message-Boards-thumbnail-2015.png

test123 kjk
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wave Kids™ Unveils New Flavors for Kids' Drinks

Updated Category News Views 4

Sparking a Fresh Wave in the Kids' Beverage Market Alright, let me tell you about a new player plowing into the kids' drink scene. Wave Kids™, a brand that's making waves—pun intended—has a fresh lineup that screams 'fun' and 'healthy' in equal measure. Just coinciding with back-to-school season, this Scottsdale, Arizona outfit has rolled out not one or two, but...

Continue Reading
Are FULC, WEAV, TECH Shareholders Getting a Raw Deal?

Updated Category News Views 2

Pocketing Insider Gains Amidst Shareholder Concerns Let me tell you, it smells like another day in the financial jungle where insiders might be feasting while the regular Joe shareholders are left nibbling on crumbs. Fulcrum Therapeutics, Weave Communications, and Bio-Techne are in the crosshairs for deals that may favor those on the inside track over you and me, the...

Continue Reading
RARE Foundation Rebrands, Focus Still Strong

Updated Category News Views 2

Unveiling the RARE Foundation's New Identity In the stock market, you ride waves of change, and let me tell you, it ain't just stocks and bonds that change names and faces. Case in point: The EveryLife Foundation for Rare Diseases has spiffed up as the RARE Foundation. New name, new logo, the whole enchilada. This isn't just a cosmetic touch-up, though. It's about...

Continue Reading
Give Lively & Change Simplify CA Nonprofit Compliance

Updated Category News Views 0

A Fresh Wind Blowing for California Nonprofits So, here's a twist in the nonprofit world that's stirring the pot just right. Give Lively and Change have partnered up to tackle the thorny issue of regulatory compliance in California. It's a big win for the nonprofits looking to keep fundraising through Give Lively without getting tangled in the bureaucratic web spun up by...

Continue Reading
Sacrifice Unending: 9/11's Lingering Health Toll

Updated Category News Views 1

The Unseen Toll of 9/11 on the Firefighter Community Two and a half decades since that fateful morning of September 11, 2001, we're staring at a grim reality. The heroic souls of the New York City Fire Department (FDNY)—those who ran toward peril when others ran away—are still paying the price. Incredibly, more than 400 FDNY members have succumbed to World Trade...

Continue Reading
EFSI Shareholders on Alert Amid M&A Deal Scrutiny

Updated Category News Views 3

Eagle Financial Services Under the Microscope A buzz is picking up in the world of mergers and acquisitions, and this time, it's Eagle Financial Services, Inc. (NASDAQ: EFSI) caught in the crosshairs. What's the chatter all about? Well, it looks like Juan Monteverde and his crew over at Monteverde & Associates PC have set their sights on Eagle's proposed sale to John...

Continue Reading
Fresh Thyme Empowers Local Brands in Michigan Debut

Updated Category News Views 2

A Community-Driven Retail Innovation The grocery game just got a little more personal in Michigan, and we're not talking about run-of-the-mill retail pitches. Fresh Thyme Market, known for its commitment to local and natural products, is shaking things up with their Pitch Thyme Competition. This ain’t your usual product presentation. It’s a whole new ball game where...

Continue Reading
ABC Honors 2026 Spirit of the Heart Leaders

Updated Category News Views 4

Celebrating Champions of Cardiovascular Health In a world where accolades often feel as cold as the stock market after a crash, it’s heartening to see genuine recognition for those who are making actual, lasting impact. On October 3, 2026, the Association of Black Cardiologists (ABC) will hold its annual Spirit of the Heart Awards at none other than Cipriani Wall...

Continue Reading
Woodpack Global Unveils Crate Design System: A New Era Begins

Updated Category News Views 1

Innovating the Wooden Crate Landscape An old industry got a much-needed facelift today, folks. Woodpack Global has rolled out Crate Design System™ (CDS)—a snazzy new tool that's shaking up the wooden crate design landscape. It blows the dust off outdated design methods that have been collecting cobwebs since the '60s. That's right, we’re talking about a significant...

Continue Reading
Monib Zirvi's Dermatology Excellence Honored in 2026

Updated Category News Views 3

Trailblazer in Dermatology Recognized Again Fancy yourself a star in dermatology? Well, take notes from Dr. Monib A. Zirvi. The guy just got his due recognition from Marquis Who's Who for his sizable contributions to dermatology and research. For someone who's been at this game for over two decades, Zirvi doesn't just glide by on old merits. He's the real deal, and his...

Continue Reading

Top 5 Most Recently Viewed Articles

Integrated Rail and Resources Acquisition Corp. Business Update

Updated Category News Views 154

Integrated Rail and Resources Acquisition Corp. Business Extension Integrated Rail and Resources Acquisition Corp. is taking strategic steps to extend its timeline for finalizing a business combination. Recent communications from its sponsor, DHIP Natural Resources Investments, LLC, indicate that the Company will push back its deadline from December 15, 2025, to January...

Continue Reading
Bitcoin Solaris Sees Surge in Investor Interest Pre-Launch

Updated Category News Views 124

Bitcoin Solaris: A New Era in Cryptocurrency Bitcoin Solaris (BTC-S) has become a key player in the cryptocurrency landscape, as its presale gains remarkable traction with over 11,500 investors contributing, raising more than $5 million. With less than seven weeks to go before launching on major exchanges, the excitement and confidence surrounding this innovative...

Continue Reading
QuantiPath.bio: A New Era in Food Safety Testing Solutions

Updated Category News Views 434

QuantiPath.bio: A New Identity for Food Safety Innovation In a remarkable transformation, Food Supply Security has officially adopted the name QuantiPath.bio. This bold rebranding marks a significant moment, embodying the commitment to innovation and a new vision for the future of food safety testing. The Groundbreaking Product: GenoPATHx At the forefront of QuantiPath's...

Continue Reading
Evaxion Biotech Modifies ADS Ratio Change Timeline

Updated Category News Views 139

Evaxion Biotech Announces Changes to ADS Ratio Evaxion Biotech A/S (NASDAQ: EVAX), a leader in the TechBio sector focusing on AI-powered vaccines, has made an important announcement regarding the adjustment of the ratio of its American Depositary Shares (ADS) to its ordinary shares. This decision reflects Evaxion's commitment to enhancing investor liquidity as it...

Continue Reading
AtkinsRéalis Expands Horizons with C2AE Acquisition

Updated Category News Views 149

AtkinsRéalis Expands Horizons with C2AE Acquisition AtkinsRéalis Group Inc. (TSX: ATRL) has recently enhanced its portfolio by acquiring C2AE, Inc., an established architecture and engineering firm based in Michigan. This strategic move further solidifies AtkinsRéalis’ commitment to expanding its presence within the U.S., particularly in the Upper Midwest region....

Continue Reading